Global Balantidiasis Market Size, Share, Forecast Report, 2020-2027

Balantidiasis, also known as Balantidium coli infection, is a disease caused by intestinal protozoan parasite Balantidium coli. Being transmitted through the fecal-oral route, a person acquires the disease by ingesting infective cysts from food and water contaminated by feces. The disease mainly affects large intestine. Diarrhea, weight loss, dysentery, abdominal pain, nausea, and vomiting are common symptoms for balantidiasis. The diseases is found to be prevalent in the rural areas of the developed and developing countries due to the contamination of water by the fecal matter of pigs or humans. The best remedy for the prevention of the disease are maintaining proper conditions for clean and safe drinking water. Antibiotics are most widely used for the treatment of balantidiasis.

Rising prevalence of gastrointestinal disorders, increasing number of patients and availability of treatment of balantidiasis drives the growth of the market. Additionally, the lack of hygiene and sanitation in the rural areas of developing countries is one of the many factors which affect the spread of this disease. Furthermore, rising awareness about the diseases transmitted through fecal-oral route influences the market growth. Competition among existing market players restrict the entry of new players.

The global balantidiasis market is expected to grow at a CAGR of 2.1% during the forecast period.

Key Players in the Global Balantidiasis Market

Some of the key players in this market are Pfizer (U.S.), Abbott (U.S.), GlaxoSmithKline plc. (U.K), BD (U.S.), Sandoz International GmbH (Germany), Amneal Pharmaceuticals LLC. (U.S.), Akorn, Inc. (U.S.), and PharmaDerm, a division of Fougera Pharmaceuticals Inc. (U.S.).
Segments

The global balantidiasis market is segmented on the basis of diagnosis, treatment, and end user.

On the basis of diagnosis, the market is segmented into stool examination, sigmoidoscopy, biopsy, and others.

On the basis of treatment, the market is segmented into antibiotics, appendectomy, and others. Antibiotics segment is further divided into tetracycline, metronidazole, and others.

On the basis of end user, the market is segmented into hospitals, clinics, diagnostic centers, and others.